Published in Epigenetics on July 19, 2013
Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics (2014) 0.98
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci Transl Med (2015) 0.89
Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection. J Virol (2016) 0.81
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget (2016) 0.81
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proc Natl Acad Sci U S A (2016) 0.80
Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells. Int J Cancer (2015) 0.77
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med (2014) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Genetic neuropathology of obsessive psychiatric syndromes. Transl Psychiatry (2014) 0.76
Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors. Genom Data (2015) 0.75
HES6 promotes prostate cancer aggressiveness independently of Notch signalling. J Cell Mol Med (2015) 0.75
MicroRNA expression profiling of Xp11 renal cell carcinoma. Hum Pathol (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res (2004) 54.37
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
KEGG for linking genomes to life and the environment. Nucleic Acids Res (2007) 49.37
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35
Functional discovery via a compendium of expression profiles. Cell (2000) 31.39
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2007) 22.53
Normalization of cDNA microarray data. Methods (2003) 18.69
Multiple-laboratory comparison of microarray platforms. Nat Methods (2005) 11.74
Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res (2010) 11.23
Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (2005) 10.64
Finding community structure in very large networks. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 10.30
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2011) 8.62
PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics (2005) 8.41
Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci U S A (2003) 6.87
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Statistical issues in cDNA microarray data analysis. Methods Mol Biol (2003) 4.50
The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer (2007) 4.40
No consent should be needed for using leftover body material for scientific purposes. For. BMJ (2002) 3.77
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Clinical studies of histone deacetylase inhibitors. Clin Cancer Res (2009) 2.68
An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun (2008) 2.48
Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs (2009) 1.99
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol (2007) 1.98
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett (2006) 1.62
Human Protein Reference Database and Human Proteinpedia as resources for phosphoproteome analysis. Mol Biosyst (2011) 1.62
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer (2004) 1.57
Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity (1997) 1.52
Molecular effects of genistein on male urethral development. J Urol (2011) 1.51
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1.48
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res (2009) 1.42
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Transcriptional regulation of antigen presentation. Curr Opin Immunol (2004) 1.34
β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res (2011) 1.33
Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother (2006) 1.30
Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells (2009) 1.30
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res (2009) 1.19
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother (2012) 1.15
Gene expression pathways of high grade localized prostate cancer. Prostate (2011) 1.12
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res (2011) 1.10
MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov (2012) 1.07
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys (2008) 1.03
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol (1994) 0.94
Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol (2011) 0.93
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res (2008) 0.87
Assessment of the mitotic spindle assembly checkpoint (SAC) as the target of anticancer therapies. Curr Cancer Drug Targets (2009) 0.86
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett (2011) 0.85
Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol Cancer Ther (2008) 0.85
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009) 3.25
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40
Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest (2002) 2.33
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Digital pathology: current status and future perspectives. Histopathology (2011) 2.18
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics. Am J Surg Pathol (2014) 1.95
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 1.89
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (2012) 1.87
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem (2009) 1.83
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology (2009) 1.80
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Alternatives for randomization in lifestyle intervention studies in cancer patients were not better than conventional randomization. J Clin Epidemiol (2012) 1.71
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med (2011) 1.66
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat (2009) 1.65
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 1.58
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
Effects of age and heart failure on human cardiac stem cell function. Am J Pathol (2011) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Molecular effects of genistein on male urethral development. J Urol (2011) 1.51
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Echocardiographic left ventricular mass in a multiethnic Southeast Asian population: proposed new gender and age-specific norms. Echocardiography (2008) 1.48
Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation. Am J Cardiol (2007) 1.44
Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One (2013) 1.42
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med (2008) 1.41
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One (2010) 1.40
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Volumetric intravascular ultrasound assessment of mechanisms and results of stent expansion in heart transplant patients. Catheter Cardiovasc Interv (2012) 1.39
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv (2011) 1.38
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res (2011) 1.37
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep) (2007) 1.35
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol (2010) 1.34
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol (2013) 1.32
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res (2004) 1.31
Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells (2009) 1.30
c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol (2006) 1.30
How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer (2010) 1.30
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med (2012) 1.29
COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest (2010) 1.28
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer (2012) 1.28
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol (2003) 1.27
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One (2007) 1.26
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate (2010) 1.25
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol (2005) 1.25
Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol (2005) 1.22
Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc (2007) 1.22
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem (2004) 1.21
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol (2010) 1.19
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res (2008) 1.18
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer (2012) 1.18
hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem (2004) 1.18
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat (2007) 1.16
Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene (2004) 1.16
Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics (2010) 1.16